Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Condition: Breast Cancer Interventions: Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2; Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2; Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg; Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor: New York University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Herceptin | Inflammatory Breast Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Taxotere